Immunotherapy combo studied for rare tumors, but trial stopped early
NCT ID NCT02938793
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This study tested a combination of two immunotherapy drugs (durvalumab and tremelimumab) in people with advanced rare solid tumors that had not responded to standard treatments. The goal was to see if the drugs could shrink tumors and to check for side effects. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Greenville Health System Cancer Institute
Greenville, South Carolina, 29605, United States
Conditions
Explore the condition pages connected to this study.